SURFACE LOGIX INC. TO PRESENT AT THE FUTURE LEADERS IN THE BIOTECH INDUSTRY CONFERENCE
BOSTON, Mass. (March 26, 2007) – Surface Logix Inc.
announced today that Jim Mahoney, President and
Chief Executive Officer, will present an update of
the company’s drug development pipeline at the 14th
annual Future Leaders in the Biotech Industry
conference on March 29, 2007, at 3:30 p.m. Eastern
Time from Millennium Broadway Hotel in New York
City.
Surface
Logix Inc. currently has two programs in human clinical
trials with a third program approaching its initial
regulatory submission. Mr. Mahoney will discuss the
latest results for SLx-2101, currently in Phase IIa, a
second generation PDE5 inhibitor designed to address
cardiovascular indications, including Raynaud’s Syndrome
and Hypertension; and SLx-4090, soon to be in Phase IIa,
a first-in-class enterocyte specific MTP inhibitor
targeting
unmet
needs in dyslipidemia, metabolic disorders and obesity.
About
Surface Logix Inc.
Surface
Logix Inc. uses its expertise in biophysical chemistry
to create new small molecule drugs that are optimized to
meet the challenges of human physiology. The company is
advancing multiple internal programs focused primarily
on cardiovascular, metabolic, inflammatory and fibrotic
diseases. For more information, please visit http://www.surfacelogix.com.
Contact:
Leland Webster, Ph.D., M.B.A.
Surface Logix Inc.
Vice President, Corporate Development
617.746.8520
Media:
Kari Watson
MacDougall Biomedical Communications Inc.
kwatson@macbiocom.com
508.647.0209
|
